[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1545516T3 - Topical formulation comprising at least 10% metronidazole in vaseline and its use in the anal and rectal region - Google Patents

Topical formulation comprising at least 10% metronidazole in vaseline and its use in the anal and rectal region

Info

Publication number
DK1545516T3
DK1545516T3 DK03792521T DK03792521T DK1545516T3 DK 1545516 T3 DK1545516 T3 DK 1545516T3 DK 03792521 T DK03792521 T DK 03792521T DK 03792521 T DK03792521 T DK 03792521T DK 1545516 T3 DK1545516 T3 DK 1545516T3
Authority
DK
Denmark
Prior art keywords
metronidazole
vaseline
anal
composition
topical formulation
Prior art date
Application number
DK03792521T
Other languages
Danish (da)
Inventor
David Nigel Armstrong
Original Assignee
Sla Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sla Pharma Ag filed Critical Sla Pharma Ag
Application granted granted Critical
Publication of DK1545516T3 publication Critical patent/DK1545516T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
DK03792521T 2002-08-26 2003-08-22 Topical formulation comprising at least 10% metronidazole in vaseline and its use in the anal and rectal region DK1545516T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40635102P 2002-08-26 2002-08-26
PCT/GB2003/003692 WO2004017962A2 (en) 2002-08-26 2003-08-22 Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region

Publications (1)

Publication Number Publication Date
DK1545516T3 true DK1545516T3 (en) 2008-12-15

Family

ID=31946965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792521T DK1545516T3 (en) 2002-08-26 2003-08-22 Topical formulation comprising at least 10% metronidazole in vaseline and its use in the anal and rectal region

Country Status (29)

Country Link
US (5) US20060240123A1 (en)
EP (1) EP1545516B1 (en)
KR (1) KR100991054B1 (en)
CN (2) CN1678309A (en)
AT (1) ATE406890T1 (en)
AU (1) AU2003260736B8 (en)
BR (1) BR0313824A (en)
CA (1) CA2496864C (en)
CR (1) CR7768A (en)
CU (1) CU23436B6 (en)
CY (1) CY1108601T1 (en)
DE (1) DE60323380D1 (en)
DK (1) DK1545516T3 (en)
EA (1) EA008150B1 (en)
ES (1) ES2312847T3 (en)
HK (1) HK1077758A1 (en)
HR (1) HRP20050258A2 (en)
IL (1) IL167069A (en)
IS (1) IS7761A (en)
MA (1) MA27520A1 (en)
MX (1) MXPA05002033A (en)
NO (1) NO333670B1 (en)
NZ (1) NZ538998A (en)
PL (1) PL375560A1 (en)
PT (1) PT1545516E (en)
RS (1) RS20050170A (en)
UA (1) UA81638C2 (en)
WO (1) WO2004017962A2 (en)
ZA (1) ZA200502365B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
BR0314916A (en) 2002-10-25 2005-08-16 Foamix Ltd Pharmaceutical and Cosmetic Foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
AU2004317993A1 (en) * 2004-03-16 2005-10-13 Interthyr Corporation Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
ITMI20041295A1 (en) 2004-06-25 2004-09-25 Cosmo Spa ORAL ANTI-MICROBIAL PHARMACEUTICAL COMPOSITIONS
CN1291754C (en) * 2005-07-12 2006-12-27 李赴朝 Localized anesthesia synergistic delay agent
FR2899475A1 (en) * 2006-04-10 2007-10-12 Galderma Res & Dev Composition, useful to prepare a drug to treat and/or the prevent rosacea, preferably vascular disorders caused by rosacea, comprises metronidazole and zinc, in a medium
CN100421648C (en) * 2006-08-15 2008-10-01 苏州市立医院 Hydrocortisone clyster agent and method for preparing the same
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090324736A1 (en) * 2008-05-07 2009-12-31 Salix Pharmaceuticals, Ltd. Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
IT1396731B1 (en) * 2009-11-25 2012-12-14 Masci PHARMACEUTICAL COMPOSITION BASED ON METRONIDAZOLE AND ZINC OXIDE FOR THE TOPIC TREATMENT OF ACUTE AND CHRONIC DISTROPHIC AND POST-OPERATIVE ANALYSIS
US8952057B2 (en) * 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US20120177582A1 (en) * 2011-01-11 2012-07-12 Ramirez Jose E Compositions for anorectal use and methods for treating anorectal disorders
US20140256661A1 (en) * 2011-07-15 2014-09-11 David Nigel Armstrong Pharmaceutical compositions for rectal administration
CN102920665B (en) * 2012-12-04 2014-06-11 四川省川龙动科药业有限公司 Colon-targeted zinc oxide pellet and preparation method thereof
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
KR102377396B1 (en) * 2014-04-10 2022-03-22 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 Compositions and methods for induction of TH17 cells
RU2605615C2 (en) * 2014-07-15 2016-12-27 Общество с ограниченной ответственностью "Гелизовит" Rectal polycomplex gel for treatment of ulcerative colitis, crohn's disease, fistulas and complications caused by these diseases
WO2016010611A1 (en) 2014-07-18 2016-01-21 Ohio University Methods and compositions to modify gsk-3 activity
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
MX2017011630A (en) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Compositions and methods for treating rosacea and acne.
US20190175558A1 (en) * 2017-12-07 2019-06-13 S.L.A. Pharma Ag Topical pharmaceutical compositions for treatment of tissue damage
US20210322458A1 (en) * 2020-04-20 2021-10-21 Gregg Tobin Methods and compositions for treatment of burns, joint pain, and fungal infections
WO2022123305A1 (en) * 2020-12-07 2022-06-16 S.L.A. Pharma Ag Compositions comprising metronidazole for treatment of diabetic foot ulcers and venous ulcers
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620674A1 (en) * 1986-06-20 1987-12-23 Nattermann A & Cie Ointment for the treatment of skin diseases
US4957918A (en) * 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
CA2011423A1 (en) * 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US5143934A (en) 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
IN171919B (en) * 1989-11-01 1993-02-06 Mcneil Ppc Inc
RU2128040C1 (en) 1996-03-19 1999-03-27 Николай Васильевич Дмитриенко Liniment "fusol" as a drug showing antiinflammatory, wound-healing and regenerative effects and a method of its preparing
CN1202358A (en) * 1997-06-12 1998-12-23 马秀珍 Medicinal liquid and ointment for curing ache folliculitis and eczema
US5948400A (en) * 1997-11-20 1999-09-07 Smith & Nephew Inc. Method of applying a pressure-sensitive adhesive wound dressing and water-based skin treatment composition
CN1304001C (en) * 1999-07-16 2007-03-14 株式会社昭荣 Nitroimidazole external preparations for dermatosis
CN1291484A (en) 2000-08-18 2001-04-18 周文山 Medicine for treating prostatic diseases
UA53946A (en) 2002-03-25 2003-02-17 Донецький Державний Медичний Університет Ім. М. Горького Composition for treating generalized parodontitis in hiv-infected persons
UA53946U (en) 2010-04-12 2010-10-25 Тернопольский Национальный Технический Университет Имени Ивана Пулюя Process for the preparation of modified epoxy composite coating

Also Published As

Publication number Publication date
NO20051542L (en) 2005-05-19
KR20050059140A (en) 2005-06-17
US20060240123A1 (en) 2006-10-26
ATE406890T1 (en) 2008-09-15
US20160346253A1 (en) 2016-12-01
CA2496864A1 (en) 2004-03-04
CN101843614B (en) 2013-05-22
DE60323380D1 (en) 2008-10-16
ZA200502365B (en) 2006-07-26
US20140271921A1 (en) 2014-09-18
US10653671B2 (en) 2020-05-19
AU2003260736B8 (en) 2009-04-23
US20130217741A1 (en) 2013-08-22
US9655883B2 (en) 2017-05-23
NO333670B1 (en) 2013-08-05
UA81638C2 (en) 2008-01-25
KR100991054B1 (en) 2010-10-29
US20100305178A1 (en) 2010-12-02
CN101843614A (en) 2010-09-29
PL375560A1 (en) 2005-11-28
NZ538998A (en) 2007-12-21
ES2312847T3 (en) 2009-03-01
HRP20050258A2 (en) 2005-10-31
EP1545516B1 (en) 2008-09-03
MA27520A1 (en) 2005-09-01
CR7768A (en) 2005-07-15
JP2006501235A (en) 2006-01-12
HK1077758A1 (en) 2006-02-24
AU2003260736A1 (en) 2004-03-11
EA008150B1 (en) 2007-04-27
PT1545516E (en) 2008-12-02
MXPA05002033A (en) 2005-10-19
BR0313824A (en) 2005-07-05
US10881640B2 (en) 2021-01-05
WO2004017962A2 (en) 2004-03-04
WO2004017962A3 (en) 2004-04-15
JP4744143B2 (en) 2011-08-10
AU2003260736B2 (en) 2009-04-02
RS20050170A (en) 2007-11-15
CA2496864C (en) 2009-04-28
CY1108601T1 (en) 2014-04-09
CU23436B6 (en) 2009-10-16
IL167069A (en) 2011-03-31
EP1545516A2 (en) 2005-06-29
CN1678309A (en) 2005-10-05
EA200500401A1 (en) 2005-08-25
US10709689B2 (en) 2020-07-14
IS7761A (en) 2005-03-21

Similar Documents

Publication Publication Date Title
DK1545516T3 (en) Topical formulation comprising at least 10% metronidazole in vaseline and its use in the anal and rectal region
NO20001567L (en) Bioadhesive compositions and methods for topical administration of active agents
TW200505508A (en) Methods of administering a dermatological agent to a subject
BR0311939A (en) pharmaceutical composition, method for treating inflammation in a mammal and use of a protective tissue cytokine
TR200103474T2 (en) New uses of the compositions as an antibacterial agent
WO2003018619A3 (en) Antimicrobial and anti-inflammatory peptides
NO20050537L (en) Use of HMGB1 in the treatment of tissue damage and / or to promote tissue repair
ATE275393T1 (en) SOLID DISPERSIONS WITH NITRATACTIVE ACTIVE INGREDIENTS
SE0402762D0 (en) Indazole sulphonamide derivatives
TR199802060T2 (en) Use of aminoisoquinolins and aminopyridine derivatives as anti-inflammatory agents.
HUP0101374A2 (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
NO20031648L (en) Pharmaceutical solutions of modafinil compounds
SE9802794D0 (en) New compounds
TR200002580T2 (en) Substituted bisindolimaleimides used to inhibit cell proliferation
SE9802793D0 (en) New compounds
ECSP055844A (en) NEW TRICYCLE COMPOUNDS
TR200103004T2 (en) Pyrrolidincarbonylamino cyclic disulfides.
DK1450792T3 (en) Benzazole derivatives for the treatment of scleroderma
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
DE60100666D1 (en) VETERINARY COMPOSITIONS FOR TREATING PARASITAL DISEASES
FR2737135B1 (en) FLUORINATED CONTINUOUS PHASE REVERSE GELS
DE50308492D1 (en) CONNECTIONS INHIBITING FACTOR XA ACTIVE T
EA201100575A1 (en) COMPOSITION OF DIHYDRATE 3- (2,2,2-TRIMETHYL HYDRAZINIUM) PROPIONATE FOR EXTERNAL LOCAL APPLICATION
TR200103238T2 (en) Cis- [4-Siano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylate] salts
SE9902596D0 (en) Pharmaceutically active compounds